Enlivex Therapeutics Ltd. (TLV:ENLV)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
392.70
-4.80 (-1.21%)
Jul 8, 2025, 5:24 PM IDT
-20.99%
Market Cap 93.82M
Revenue (ttm) n/a
Net Income (ttm) -53.34M
Shares Out n/a
EPS (ttm) -2.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,512
Average Volume 30,151
Open 397.50
Previous Close 397.50
Day's Range 387.30 - 400.00
52-Week Range 309.30 - 628.90
Beta 0.74
RSI 54.25
Earnings Date Jun 13, 2025

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Country Israel
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol ENLV
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.